<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134405</url>
  </required_header>
  <id_info>
    <org_study_id>037-OTC-1203i</org_study_id>
    <nct_id>NCT02134405</nct_id>
  </id_info>
  <brief_title>Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia</brief_title>
  <official_title>Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang Provincial Hospital of TCM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-Asian-centre randomised controlled trial of Rebamipide alone vs Rebamipide&#xD;
      with Esomeprazole in the treatment of adult patients with Functional Dyspepsia. The&#xD;
      hypothesis is that a combination therapy is superior to mono-therapy in the control of&#xD;
      patients' symptoms and quality of life improvement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To assess the efficacy of Rebamipide in combination with Esomeprazole in&#xD;
      the improvement of symptoms of Functional Dyspepsia in Asian patients compared to&#xD;
      Esomeprazole alone Secondary Objective: i. To assess the efficacy of Rebamipide in&#xD;
      combination with Esomeprazole in the improvement of quality of life in Asian patients with&#xD;
      Functional Dyspepsia compared to Esomeprazole alone ii. To assess the cost-effectiveness of&#xD;
      Rebamipide in combination with Esomeprazole compared to Esomeprazole alone after 8, 12 weeks&#xD;
      of treatment iii. To assess the safety of Rebamipide in combination with Esomeprazole in&#xD;
      adults with functional dyspepsia after 8 weeks of treatment.&#xD;
&#xD;
      Trial Design Multi-national, randomised, double-blind, placebo-controlled study&#xD;
&#xD;
      Treatment Group:&#xD;
&#xD;
        -  Study Group: Rebamipide + Esomeprazole&#xD;
&#xD;
        -  Control Group: Rebamipide placebo + Esomeprazole Investigational Product (IP):&#xD;
           Rebamipide 100 mg tablet Rebamipide placebo tablet Esomeprazole 20 mg tablet Dosage&#xD;
           regimen: Administration route: PO Rebamipide 100 mg t.i.d Rebamipide placebo t.i.d&#xD;
           Esomeprazole 20 mg o.d Target Population Male or female subjects aged from 18 years to&#xD;
           less than 80 years with a diagnosed of Functional Dyspepsia (FD) Primary Endpoint:&#xD;
           Change in Leeds Dyspepsia Questionnaire (LDQ) total score from baseline to 8 weeks of&#xD;
           treatment Secondary Endpoints: 1. The change in Health-Related Quality of Life (EQ-5D)&#xD;
           from baseline to 8 weeks of treatment 2. The cost effectiveness based on cost per QALY&#xD;
           gained between the study group compared to the control group at 8, 12 weeks 3. The&#xD;
           change in Leeds Dyspepsia Questionnaire (LDQ) total score and Health-Related Quality of&#xD;
           Life (EQ-5D) from baseline to 12 weeks Inclusion Criteria: 1. Patients diagnosed with&#xD;
           Functional Dyspepsia using Rome III diagnostic criteria 2. Age ≥ 18 years, &lt; 80 years 3.&#xD;
           Subject who has ability to provide written informed consent and willingness to comply&#xD;
           with the requirement of the protocol 4. Able to communicate in English, Malay or&#xD;
           Mandarin languages 5. Patients on prior dyspepsia treatment - after washout period of 1&#xD;
           week Exclusion Criteria: 1. Patients with known hypersensitivity to Rebamipide and/or&#xD;
           Esomeprazole and any other component of these formulations.&#xD;
&#xD;
           2. Pregnant, nursing, and childbearing potential women who is unwilling to effective&#xD;
           contraception; for example, oral contraceptives, hormonal methods, placement of an&#xD;
           intrauterine device (IUD) or intrauterine system (IUS), barrier methods (i.e., condom or&#xD;
           occlusive cap with spermicidal foam/gel/film/cream/ suppository), male sterilization,&#xD;
           and true abstinence 3. Presence of family history of GI malignancy or alarm features&#xD;
           suggested malignancy - e.g. Unintentional weight loss (more than 10% of body weight in&#xD;
           recent 6 months), GI bleeding 4. Patients consuming regular Aspirin or NSAIDs (except&#xD;
           low-dose Aspirin at a dose of 325 mg/day or less for cardiovascular prophylaxis) 5.&#xD;
           History of erosive esophagitis, peptic ulcer disease within 1 year prior to the&#xD;
           screening 6. History of gastrointestinal (GI) malignancy, primary esophageal motility&#xD;
           disorder, documented upper GI surgery 7. Patients with any hepatobiliary or pancreatic&#xD;
           diseases 8. Patients with severe depression, anxiety, or other psychological disorder 9.&#xD;
           Patients with any terminal disease 10. Presence of irritable bowel syndrome (Rome III&#xD;
           criteria) or inflammatory bowel disease (IBD) 11. Necessary to have a continuous&#xD;
           concomitant treatment with sucralfate, quinidine, warfarin, phenytoin, bisphosphonates,&#xD;
           methotrexate, ketoconazole, fluconazole, itaconazole, diazepam, anti-cholinergics,&#xD;
           H2RAs, PPIs (except study drug), prokinetics, and/or NSAIDs (except topical use of&#xD;
           NSAIDs; in systemic NSAIDs ≤2 days/week) 12. Use of PPIs (except study drug), H2RAs,&#xD;
           prokinetics, antibiotics (except topical use), misoprostol, or bismuth compounds within&#xD;
           1 week prior to the screening, and who were taking antibiotics used to eradicate&#xD;
           Helicobacter pylori within 4 weeks prior to the screening 13. Unable to communicate in&#xD;
           English, Malay, or Mandarin 14. Other conditions determined by the investigator to be&#xD;
           inappropriate for this clinical study Duration of treatment: 8 weeks Number of subjects:&#xD;
           Ninety-three patients per each group with 90% power at the 0.05 significance level were&#xD;
           used. Considering 10% drop-out rate, total of 208 patients (104 patients per each group)&#xD;
           will be enrolled in the study.&#xD;
&#xD;
      Total: 208 Study Group: 104 Control Group: 104 Anticipated Timelines: Duration of trial: 18&#xD;
      months Start of recruitment: March 2014 End of recruitment: August 2015 Last subject out: Oct&#xD;
      2015&#xD;
&#xD;
      Statistical Methodology:&#xD;
&#xD;
      Primary Endpoint Change in Leeds Dyspepsia Questionnaire (LDQ) total score from baseline to 8&#xD;
      weeks of treatment&#xD;
&#xD;
      Secondary Endpoint&#xD;
&#xD;
        1. The change in Health-Related Quality of Life (EQ-5D) from baseline to 8 weeks of&#xD;
           treatment&#xD;
&#xD;
        2. The cost effectiveness based on cost per QALY gained between the study groups compared&#xD;
           to the control group at 8, 12 weeks&#xD;
&#xD;
        3. The change in Leeds Dyspepsia Questionnaire (LDQ) total score and Health-Related Quality&#xD;
           of Life (EQ-5D) from baseline to 12 weeks&#xD;
&#xD;
      Summary statistics of the endpoints will be provided. Mean change will be evaluated by two&#xD;
      sample t-test or Wilcoxon's rank sum test according to the normal distribution of analyzed&#xD;
      variable.&#xD;
&#xD;
      Safety Endpoint&#xD;
&#xD;
        1. Adverse events The number of cases of AEs and the proportion of patients who experienced&#xD;
           AEs will be summarized by descriptive statistics (frequency and proportion) for each&#xD;
           study group.&#xD;
&#xD;
        2. Laboratory Test and Vital Signs All laboratory values and vital signs will be compared&#xD;
           within study group and between study groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dyspepsia symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <description>To assess the efficacy of Rebamipide in combination with Esomeprazole in the improvement of symptoms of Functional Dyspepsia in Asian patients compared to Esomeprazole alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>8 weeks</time_frame>
    <description>i. To assess the efficacy of Rebamipide in combination with Esomeprazole in the improvement of quality of life in Asian patients with Functional Dyspepsia compared to Esomeprazole alone</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Financial costs</measure>
    <time_frame>12 weeks</time_frame>
    <description>To assess the cost-effectiveness of Rebamipide in combination with Esomeprazole compared to Esomeprazole alone after 8, 12 weeks of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>To assess the safety of Rebamipide in combination with Esomeprazole in adults with functional dyspepsia after 8 weeks of treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Rebamipide and Esomeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rebamipide tablets 100mg tid for 8 weeks Esomeprazole tablets 20mg od for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rebamipide and placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo drug with Rebamipide 100mg tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebamipide</intervention_name>
    <description>Rebamipide 100mg tid</description>
    <arm_group_label>Rebamipide and Esomeprazole</arm_group_label>
    <arm_group_label>Rebamipide and placebo</arm_group_label>
    <other_name>Mucosta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Esomeprazole)</intervention_name>
    <description>Sugar pill manufactured to mimic Esomeprazole</description>
    <arm_group_label>Rebamipide and placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Esomeprazole tablets 20mg o.d. for 8 weeks</description>
    <arm_group_label>Rebamipide and Esomeprazole</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with Functional Dyspepsia using Rome III diagnostic criteria&#xD;
&#xD;
          2. Age ≥ 18 years, &lt; 80 years&#xD;
&#xD;
          3. Subject who has ability to provide written informed consent and willingness to comply&#xD;
             with the requirement of the protocol&#xD;
&#xD;
          4. Able to communicate in English, Malay or Mandarin languages&#xD;
&#xD;
          5. Patients on prior dyspepsia treatment - after washout period of 1 week&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with known hypersensitivity to Rebamipide and/or Esomeprazole and any other&#xD;
             component of these formulations.&#xD;
&#xD;
          2. Pregnant, nursing, and childbearing potential women who is unwilling to effective&#xD;
             contraception; for example, oral contraceptives, hormonal methods, placement of an&#xD;
             intrauterine device (IUD) or intrauterine system (IUS), barrier methods (i.e., condom&#xD;
             or occlusive cap with spermicidal foam/gel/film/cream/suppository), male&#xD;
             sterilization, and true abstinence&#xD;
&#xD;
          3. Presence of family history of GI malignancy or alarm features suggested malignancy -&#xD;
             e.g. Unintentional weight loss (≥ 10% of body weight in recent 6 months), GI bleeding&#xD;
&#xD;
          4. Patients consuming regular Aspirin or NSAIDs (except low-dose Aspirin at a dose of 325&#xD;
             mg/day or less for cardiovascular prophylaxis)&#xD;
&#xD;
          5. History of erosive esophagitis, peptic ulcer disease within 1 year prior to the&#xD;
             screening&#xD;
&#xD;
          6. History of gastrointestinal (GI) malignancy, primary esophageal motility disorder,&#xD;
             documented upper GI surgery&#xD;
&#xD;
          7. Patients with any hepatobiliary or pancreatic diseases&#xD;
&#xD;
          8. Patients with severe depression, anxiety, or other psychological disorder&#xD;
&#xD;
          9. Patients with any terminal disease&#xD;
&#xD;
         10. Presence of irritable bowel syndrome (Rome III criteria) or inflammatory bowel disease&#xD;
             (IBD)&#xD;
&#xD;
         11. Necessary to have a continuous concomitant treatment with sucralfate, quinidine,&#xD;
             warfarin, phenytoin, bisphosphonates, methotrexate, ketoconazole, fluconazole,&#xD;
             itaconazole, diazepam, anti-cholinergics, H2RAs, PPIs (except study drug),&#xD;
             prokinetics, and/or NSAIDs (except topical use of NSAIDs; in systemic NSAIDs ≤2&#xD;
             days/week)&#xD;
&#xD;
         12. Use of PPIs (except study drug), H2RAs, prokinetics, antibiotics (except topical use),&#xD;
             misoprostol, or bismuth compounds within 1 week prior to the screening, and who were&#xD;
             taking antibiotics used to eradicate Helicobacter pylori within 4 weeks prior to the&#xD;
             screening&#xD;
&#xD;
         13. Unable to communicate in English, Malay, or Mandarin&#xD;
&#xD;
         14. Other conditions determined by the investigator to be inappropriate for this clinical&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjiv Mahadeva, MRCP, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Malaya</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanjiv Mahadeva, MRCP, MD</last_name>
    <phone>60122171743</phone>
    <email>sanjiv@ummc.edu.my</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Federal Territory</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sanjiv Mahadeva, MRCP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>functional dyspepsia</keyword>
  <keyword>symptoms</keyword>
  <keyword>proton pump inhibitor</keyword>
  <keyword>gastritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

